Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2025 Jul 22.
doi: 10.1038/s41571-025-01062-6. Online ahead of print.

PROTAC SERD vepdegestrant outperforms fulvestrant for advanced-stage ER+HER2- breast cancer harbouring acquired ESR1 mutations

Patrick Neven  1 , Sileny N Han  2
Affiliations

PROTAC SERD vepdegestrant outperforms fulvestrant for advanced-stage ER+HER2- breast cancer harbouring acquired ESR1 mutations

Patrick Neven et al. Nat Rev Clin Oncol. .
No abstract available

PubMed Disclaimer

Conflict of interest statement

Competing interests: The authors declare no competing interests.

Similar articles

See all similar articles

References

    1. McDonnell, D. P., Wardell, S. E., Chang, C. & Norris, J. Next-generation endocrine therapies for breast cancer. J. Clin. Oncol. 39, 1383–1388 (2021). - PubMed - PMC
    1. Turner, N. C. et al. ESR1 mutations and overall survival on fulvestrant versus exemestane in advanced hormone receptor-positive breast cancer: a combined analysis of the phase III SoFEA and EFECT trials. Clin. Cancer Res. 26, 5172–5177 (2020). - PubMed
    1. Bidard, F. C. et al. Elacestrant (oral selective estrogen receptor degrader) versus standard endocrine therapy for estrogen receptor-positive, human epidermal growth factor receptor 2-negative advanced breast cancer: results from the randomized phase III EMERALD trial. J. Clin. Oncol. 40, 3246–3256 (2022). - PubMed - PMC
    1. Oliveira, M. et al. Camizestrant, a next-generation oral SERD, versus fulvestrant in post-menopausal women with oestrogen receptor-positive, HER2-negative advanced breast cancer (SERENA-2): a multi-dose, open-label, randomised, phase 2 trial. Lancet Oncol. 25, 1424–1439 (2024). - PubMed
    1. Jhaveri, K. L. et al. Imlunestrant with or without abemaciclib in advanced breast cancer. N. Engl. J. Med. 392, 1189–1202 (2025). - PubMed

LinkOut - more resources